Nippon Shinyaku Co., Ltd. (NPPNY)
OTCMKTS · Delayed Price · Currency is USD
5.35
0.00 (0.00%)
Jul 31, 2025, 8:00 PM EDT
bluebird bio Revenue
In the fiscal year ending March 31, 2025, Nippon Shinyaku had annual revenue of 160.23B JPY with 8.08% growth. Nippon Shinyaku had revenue of 38.91B in the quarter ending March 31, 2025, with 9.53% growth.
Revenue
160.23B JPY
Revenue Growth
+8.08%
P/S Ratio
1.40
Revenue / Employee
71.44M JPY
Employees
2,243
Market Cap
1.50B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 160.23B | 11.98B | 8.08% |
Mar 31, 2024 | 148.26B | 4.08B | 2.83% |
Mar 31, 2023 | 144.18B | 6.69B | 4.87% |
Mar 31, 2022 | 137.48B | 15.60B | 12.80% |
Mar 31, 2021 | 121.89B | 5.25B | 4.50% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
Nippon Shinyaku News
- 7 months ago - Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121 - Seeking Alpha
- 7 months ago - REGENXBIO partners with Nippon Shinyaku for MPS therapies - Seeking Alpha
- 7 months ago - Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
- 11 months ago - Week In Review: Nippon Shinyaku Signs $735m Deal For DMD Therapy - Seeking Alpha
- 11 months ago - Capricor Therapeutics partners with Nippon Shinyaku for European commercialization of Deramiocel - Seeking Alpha
- 11 months ago - EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm - Benzinga